SIBN · SI-BONE, Inc.

Current Thesis

SI-BONE’s growth-and-profitability thesis remains viable above its reclaimed August shelf; a weekly close above the $21.40 reference high would confirm renewed price strength, while a weekly close below $17 would invalidate the case. The operating evidence remains the 2026-08-03 results: second-quarter revenue of $56.01 million, up 15.2% year over year, and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $2.8 million, according to the company’s release.

The calendar has changed since the August 30 assessment. SI-BONE announced on 2026-08-31 that management will hold a Morgan Stanley healthcare-conference fireside chat on 2026-09-14. That announcement removes the previously identified absence of a scheduled company event, although it promises no financial update. Company announcement.

The inference is that the narrative is maturing — the operating case still rests on the August 3 results and August 4 analyst revisions, while the September 11 close has retreated below August 28. The conference adds a dated opportunity for management commentary; its announcement alone does not establish expanding investor participation.

Bullish and bearish views on SI-BONE, Inc.

The model's bull view on SI-BONE, Inc. (SIBN), in brief: Revenue supports the operating case. SI-BONE’s 2026-08-03 results reported second-quarter revenue of $56.01 million, up 15.2% year over year, with a 79.5% gross margin. These are measured operating results supporting the spinopelvic surgical-device growth thesis. Guidance… The bear view: Price has joined momentum lower. Adjusted daily bars show a $19.21 close and a 14-day relative strength index (RSI) of 55.1 on 2026-08-28, versus an $18.38 close and RSI of 19.8 on 2026-09-11. The earlier description of a momentum reset without price give-back no longer fits… Both cases follow in full.

Bull Case

• Revenue supports the operating case. SI-BONE’s 2026-08-03 results reported second-quarter revenue of $56.01 million, up 15.2% year over year, with a 79.5% gross margin. These are measured operating results supporting the spinopelvic surgical-device growth thesis.
• Guidance preserves the growth hurdle. The 2026-08-03 release raised the fiscal-2026 revenue guidance floor to $231 million and retained the $233 million ceiling. Delivery within that range remains the company’s published benchmark.
• A company event is confirmed. The 2026-08-31 announcement schedules management’s fireside chat for 2026-09-14 at 11:30 a.m. Eastern Time. The earlier calendar-gap argument no longer applies to September. Company announcement.

Bear Case

• Price has joined momentum lower. Adjusted daily bars show a $19.21 close and a 14-day relative strength index (RSI) of 55.1 on 2026-08-28, versus an $18.38 close and RSI of 19.8 on 2026-09-11. The earlier description of a momentum reset without price give-back no longer fits those observations.
• Adjusted profitability excludes a loss. The 2026-08-03 results reported a second-quarter net loss of $4.1 million under generally accepted accounting principles alongside $2.8 million of adjusted EBITDA. The company had not reached accounting profitability in that quarter.
• Seasonality limits near-term confirmation. On the 2026-08-03 earnings call, management guided third-quarter revenue to decline 1–2% sequentially. A decline beyond that guidance, or a reduction in the $231–233 million annual outlook, would contradict the operating case.

Setup & Price Structure

The 2026-09-11 adjusted close was $18.38, with a three-month price increase of 19.2% and a reported distance of 14.1% below the $21.40 reference 52-week high. Price remains above the $17.05 shelf identified in the August 30 published analysis as reclaimed after the August 3 results. The latest close preserves that structural reference, but the lower close and RSI weaken the evidence for renewed momentum.

The price case is explicitly conditional: a weekly close above $21.40 would constitute renewed strength before invalidation at a weekly close below $17. RSI of 19.8 on September 11 is an observable momentum reading; it does not establish that a rebound will occur. No moving-average value or participation series is available here to substantiate accumulation.

Analyst coverage is favorable but cannot be described as universally positive. Stock Analysis reports a $25 average target across nine analysts, with targets last updated on 2026-08-04; MarketBeat’s September 12 table instead lists six positive ratings and one negative rating, including Weiss Ratings’ 2026-08-20 revision within its negative category. These are different coverage universes, not evidence of a newly synchronized downgrade cycle. Stock Analysis, MarketBeat rating history.

Catalyst Calendar (next 30 days)

• ~2026-11-09 (est.) — Third-quarter results, beyond this window. MarketBeat’s September 10 calendar lists this estimated date; company confirmation is missing. The results directly test the August 3 guidance for a 1–2% sequential revenue decline and the $231–233 million fiscal-2026 outlook. MarketBeat company calendar.

Elapsed catalysts

• 2026-09-14 — Morgan Stanley healthcare conference. Management’s fireside chat is confirmed for 11:30 a.m. Eastern Time by the August 31 company announcement. Relevant confirmation would be explicit retention of the August 3 outlook; explicit deterioration in demand or guidance would weaken the thesis. The announcement does not promise either disclosure. Company announcement. (passed 6d ago)

What Would Change Our Mind

Loss of the reclaimed August shelf would end the price thesis: a weekly close below $17 would place the market below the $17.05 reference documented in the August 30 analysis. Separately, third-quarter revenue falling more than the guided 1–2% sequentially, or management cutting the $231–233 million annual outlook, would invalidate the operating premise established on August 3.

The September 14 conference occurring without new financial information would leave the operating thesis unresolved. Stronger evidence would require explicit financial confirmation; attendance itself cannot substitute for results.

Correlation Notes

This remains a single-company setup. The economic connection to Smith+Nephew is the pelvic-trauma distribution agreement signed on 2026-02-23, as documented in the August 30 coverage. That commercial relationship does not establish that the companies’ shares move together.

The September 11 price snapshot contains no matched peer-return series, and the dated closes cited here are too small a sample to support a correlation claim. No sector-wide participation conclusion follows from SI-BONE’s three-month price increase alone.